Telomere length is independently associated with all-cause mortality in chronic heart failure by Romaine, Simon P. R. et al.
                                                                    
University of Dundee
Telomere length is independently associated with all-cause mortality in chronic heart
failure










Link to publication in Discovery Research Portal
Citation for published version (APA):
Romaine, S. P. R., Denniff, M., Codd, V., Nath, M., Koekemoer, A., Anker, S. D., Cleland, J. G., Filippatos, G.,
Levin, D., Metra, M., Mordi, I. R., Ouwerkerk, W., Ter Maaten, J. M., van Veldhuisen, D. J., Zannad, F., Ng, L. L.,
van der Harst, P., Lang, C. C., Voors, A. A., ... Samani, N. J. (2021). Telomere length is independently
associated with all-cause mortality in chronic heart failure. Heart, [318654]. https://doi.org/10.1136/heartjnl-2020-
318654
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. May. 2021
Romaine et al. (2021) – Telomere length is independently associated with all-cause mortality in 
chronic heart failure 
Author Accepted Manuscript 
 
This article has been accepted for publication in Heart (2021) following peer review, and the Version 
of Record can be accessed online at http://dx.doi.org/10.1136/heartjnl-2020-318654.  
 
© Authors (or their employer(s)) 2021. 
 
 
Page | 1  
 
Telomere length is independently associated with all-cause mortality in chronic heart failure  
Short Title:  Telomere length and heart failure outcomes 
Simon P. R. Romaine, MBChB,a,b Matthew Denniff, BSc,a Veryan Codd, PhD,a,b Mintu Nath, PhD,a,b,c 
Andrea L. Koekemoer, PhD,a,b Stefan D. Anker, MD, PhD,d John G. Cleland, MD,e,f Gerasimos 
Filippatos, MD,g,h Daniel Levin, MSc,i Marco Metra, MD,j Ify R. Mordi, MD,k Wouter Ouwerkerk, 
PhD,l,m Jozine M. ter Maaten, MD, PhD,n Dirk J. van Veldhuisen, MD, PhD,n Faiez Zannad, MD, PhD,o 
Leong L. Ng, MD,a,b Pim van der Harst, MD, PhD,n Chim C. Lang, MD,k Adriaan A. Voors, MD, PhD,n 
Christopher P. Nelson, PhD,a,b Nilesh J. Samani, MD.a,b 
Affiliations:  a, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK 
  b, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK 
  c, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK 
d, Department of Cardiology (CVK), and Berlin Institute of Health Center for 
Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK), 
Charité Universitätsmedizin, Berlin, Germany. 
e, Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, 
Glasgow, UK 
f, National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, 
Imperial College, London, UK 
g, National and Kapodistian University of Athens, School of Medicine, Athens, 
Greece 
h, University of Cyprus, School of Medicine, Nicosia, Cyprus 
i, Division of Population Health and Genomics, School of Medicine, University of 
Dundee, Dundee, United Kingdom 
j, Department of Medical and Surgical Specialties, Radiological Sciences and Public 
Health, Institute of Cardiology, University of Brescia, Brescia, Italy 
k, Division of Molecular and Clinical Medicine, School of Medicine, University of 
Dundee, Dundee, United Kingdom 
l, Department of Cardiology, National Heart Center, Singapore 
m, Department of Dermatology, Amsterdam UMC, University of Amsterdam, 
Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands 
n, Department of Cardiology, University of Groningen, Groningen, The Netherlands 
o, Université de Lorraine, CHU de Nancy, Nancy, France 
 
Word Count:  3,000 
Funding: BIOSTAT-CHF was funded by a grant from the European Commission (FP7-242209-
BIOSTAT-CHF).  
Disclosures:  All authors declare no conflicts of interest relevant to the work in this manuscript. 
Address for Correspondence: Dr Simon P.R. Romaine, Department of Cardiovascular Sciences, 




Page | 2  
 
Abstract 
Objective: Patients with heart failure have shorter mean leucocyte telomere length (LTL), a marker 
of biological age, compared with healthy subjects, but it is unclear whether this is of prognostic 
significance. We therefore sought to determine whether LTL is associated with outcomes in patients 
with heart failure. 
Methods: We measured LTL in patients with heart failure from the BIOSTAT-CHF Index (N = 2,260) 
and BIOSTAT-CHF Tayside (N = 1,413) cohorts. Cox proportional hazards analyses were performed 
individually in each cohort and the estimates combined using meta-analysis. Our co-primary 
endpoints were all-cause mortality and heart failure hospitalisation.  
Results: In age- and sex-adjusted analyses, shorter LTL was associated with higher all-cause mortality 
in both cohorts individually and when combined (meta-analysis HR [per SD decrease in LTL] = 1.16 
[95% CI = 1.08 – 1.24]; P = 2.66 x 10-5), an effect equivalent to that of being four years older. The 
association remained significant after adjustment for the BIOSTAT-CHF clinical risk score to account 
for known prognostic factors (HR = 1.12 [1.05 – 1.20]; P = 1.04 x 10-3). Shorter LTL was associated 
with both cardiovascular (HR = 1.09 [95% CI = 1.00 – 1.19]; P = 0.047) and non-cardiovascular deaths 
(HR = 1.18 [1.05 – 1.32]; P = 4.80 x 10-3). There was no association between LTL and heart failure 
hospitalisation (HR = 0.99 [0.92 – 1.07]; P = 0.855). 
Conclusion: In patients with heart failure, shorter mean leucocyte telomere length is independently 
associated with all-cause mortality. 
 
Keywords: Telomere, heart failure; biological age 
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Key Questions 
What is already known about this subject? 
Telomere length is a marker of biological age, as distinct from chronological age. Patients with heart 
failure have been shown to have shorter mean leucocyte telomere length (LTL) compared with 
healthy controls. However, whether there is a relationship between LTL and prognosis in heart 
failure is unclear, with existing studies providing conflicting evidence, limited by either a small 
number of events or the inclusion of only individuals with a specific type of heart failure.  
What does this study add? 
In the largest analysis of telomere length and heart failure outcomes to date, this study provides 
strong evidence of a significant association between shorter LTL and increased all-cause mortality, 
but not heart failure hospitalisation, in patients with heart failure. Importantly, this association 
remained present after adjusting for chronological age and established prognostic risk factors. 
How might this impact on clinical practice? 
Although the study does not have an immediate impact on clinical practice, it provides a strong 
evidence base for further studies to investigate the potentially causal relationship between shorter 
telomere length and heart failure prognosis, as well as exploring the role of telomeres in heart 
failure pathogenesis. 
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Introduction 
Telomeres are dynamic complexes of repeat DNA sequences and associated proteins at the end of 
chromosomes that act to protect them during replication. There is marked inter-individual variation 
in lengths of telomeres from birth and there is strong genetic determination of telomere length.[1] 
Furthermore, telomeres shorten with each cell division and in response to environmental 
stresses.[2] When shortening reaches a critical point, telomere damage signalling induces cellular 
senescence and altered transcriptional profiles, including the production of inflammatory 
mediators.[2,3] As such, shorter telomere length is considered a marker of biological age and has 
been increasingly linked to a wide variety of common age-associated diseases.[2,4,5] 
Patients with heart failure have been reported to have shorter mean leucocyte telomere length (LTL) 
than healthy controls.[6] However, very few studies have investigated whether there is a 
relationship between telomere length and prognosis in heart failure and these have provided 
conflicting evidence, limited either by a small number of events or the inclusion of only individuals 
with a specific type of heart failure.[7,8] Therefore, we sought to determine the association between 
LTL and prognosis in heart failure patients (defined as all-cause mortality and unscheduled heart 
failure hospitalisation) in a large, observational study of patients with both reduced ejection fraction 








These analyses used data from BIOSTAT-CHF, a European-wide multicentre observational study of 
patients with worsening symptoms of heart failure.[9,10] The study consists of an Index cohort 
(N=2,516) recruited from 69 centres across 11 European countries and a second (Tayside) cohort 
(N=1,738) recruited from six centres across Scotland, both between 2010 and 2014. 
Key inclusion criteria for the Index cohort were symptoms of new-onset or worsening heart failure, 
along with objective evidence of cardiac dysfunction, defined as left ventricular ejection fraction ≤ 
40% and/or plasma B-type natriuretic peptide (BNP) >400 pg/mL and/or plasma N-terminal 
prohormone of BNP (NT-proBNP) >2,000 pg/mL. Key inclusion criteria for the Tayside cohort were a 
confirmed diagnosis of heart failure and a previously documented admission with heart failure that 
required treatment with diuretics. Patients in both cohorts were ≥18 years of age, receiving oral or 
intravenous diuretics but suboptimal medical therapy, defined as <50% target doses of angiotensin 
converting enzyme inhibitors/angiotensin II receptor blockers and/or beta-blockers, according to 
2008 European Society of Cardiology guidelines.[11] Patients were recruited either as in-patients or 
out-patients and underwent optimisation of heart failure therapy during the first three months of 
the study. 
All patients provided written informed consent to participate in BIOSTAT-CHF and its sub-studies, 
which were conducted in concordance with the declaration of Helsinki and approved by national and 
local ethics committees. 
Outcome measurements 
We employed two co-primary endpoints: all-cause mortality and unscheduled heart failure 
hospitalisation. We chose to analyse these endpoints separately as different factors may contribute 
to these outcomes and our primary goal was to address a biological question rather than an overall 
clinical outcome/benefit question. Secondary endpoints were cardiovascular mortality and non-
cardiovascular mortality, as determined by the BIOSTAT-CHF principal investigators.[9] 
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Clinical risk score 
To adjust our survival analyses for clinical and laboratory variables already known to affect 
prognosis, we employed BIOSTAT-CHF clinical risk scores for all-cause mortality and heart failure 
hospitalisation.[10] We selected these scores as they were derived specifically from within BIOSTAT-
CHF and have been shown to outperform previously published risk prediction models in our 
cohorts.[10] The components of each score and their cut-offs are as follows: for mortality = age (>70 
years), blood urea nitrogen (>11 mmol/L), NT-proBNP (>4,000 pg/mL), haemoglobin (<12 g/dL) and 
beta-blocker use at baseline; for heart failure hospitalisation = age, heart failure hospitalisation in 
the previous year, peripheral oedema, systolic blood pressure (<140 mmHg) and estimated 
glomerular filtration rate (eGFR; <40 mL/min).[10] Adjustment for the BIOSTAT-CHF clinical risk 
scores was achieved by stratifying analyses by the appropriate point score model. 
Telomere length measurement 
Mean LTL was measured using a well-established quantitative polymerase chain reaction (qPCR) 
based technique and expressed as a ratio (T/S) of telomere repeat length (T) to copy number of a 
single copy gene, 36B4 (S) for each sample. Full details of this method have been published 
previously,[12] and additional details are provided in the Supplementary Methods and 
Supplementary Table 1. To facilitate comparisons across the two cohorts, telomere lengths were Z-
standardised.  
Statistical analyses 
All statistical analyses were performed using R Version 3.4.4 in RStudio Version 1.1.453.[w1,w2] We 
confirmed normal distribution of LTLs prior to analyses and therefore transformation was not 
performed. The associations of LTL with baseline demographic and clinical characteristics (including 
age, sex, ischaemic aetiology, and heart failure classification) were assessed using both univariate 
and multivariate (age- and sex-adjusted) linear regression, with LTL as the response variable. 
The associations of LTL with all-cause mortality and heart failure hospitalisation were assessed using 
Cox proportional hazards regression using the ‘survival’ package in R.[w3] We confirmed that 
assumptions for each test were met, including proportionality of hazards, which was assessed using 
individual and global Schoenfeld tests. Telomere length was analysed as both a continuous trait 
(with hazard ratios presented per SD decrease in LTL) and split into quartiles (with hazard ratios 
presented relative to those with the longest LTL). We employed two models for each endpoint: 
Model 1 = LTL adjusted for age and sex; Model 2 = LTL adjusted for age, sex, and BIOSTAT-CHF risk 
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score. Sensitivity analyses replacing the risk scores with their individual components were also 
performed. Cause-specific survival analyses were performed by censoring patients who died of an 
alternative cause at the time of death. Interactions were tested by adding multiplicative terms, in 
addition to the main effects, to the respective Cox models. We performed a sensitivity analysis for 
the hospitalisation outcome to allow for the competing risk of death.[13] Competing risk models 
were adjusted for age, sex and BIOSTAT-CHF risk score, allowing the risk score to vary over time and 
satisfy the proportional hazards assumption. All analyses were performed separately in each cohort. 
Combined estimates were generated using fixed-effects inverse-weighted meta-analyses with the R 
package ‘meta’.[w4] Details of data visualisation and the generation of age- and sex-adjusted LTL 
quartiles are provided in the Supplementary Methods. 
To aid interpretation of the impact of LTL on all-cause mortality, we convert the estimate for LTL into 
an equivalent in terms of increasing chronological age. To achieve this, we calculate the ratio of the 
LTL and age log-hazard ratios from the survival model for all-cause mortality (Model 1). 
Statistical significance was defined as P<0.05; formal adjustments for multiple testing were not 
applied. 
Patient and public involvement 
Patients or the public were not directly involved in the design, conduct, reporting, or dissemination 
of this research. 
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Results 
Patient characteristics and outcomes 
After exclusion of patients with no outcome data (N=145), no or insufficient quality DNA (N=431), 
and LTL outliers (N=5), a total of 3,673 patients were included in the current analyses (Index = 2,260; 
Tayside = 1,413). Key baseline characteristics of both cohorts are shown in Table 1, with extended 
characteristics shown, per TL quartile, in Supplementary Tables 2A and 2B. Differences in the 
proportion of patients with HFpEF between cohorts are reflective of differences in inclusion criteria. 
In the Index cohort, after a median follow-up of 21.3 months (IQR = 15.4 – 27.1), there were 596 
(26.4%) deaths and 571 (25.3%) patients hospitalised for heart failure. Follow-up in the Tayside 
cohort was longer (median [IQR] = 23.6 [14.2 – 34.3] months) and a higher proportion of patients 
died (32.6%) or were hospitalised for heart failure (26.4%). When follow-up was limited to one or 
two years, event numbers were similar (Supplementary Table 3). 
Confirmation of known telomere length associations 
Using multivariate linear regression with age and sex as independent variables, we confirmed the 
known association of LTL with age in both cohorts, with older patients having shorter telomeres 
(Index: B=-0.033, P=2.05x10-92; Tayside: B=-0.023, P=1.92x10-19; Supplementary Figure 1). Similarly, 
we observed the established finding that men have shorter telomeres than women (Index: B=-0.271, 
P=1.08x10-10; Tayside: B=-0.191, P=4.10x10-4; Supplementary Figure 1). 
Telomere length and heart failure subgroups 
After adjusting for age and sex using multivariate linear regression, we found that patients with 
ischaemic aetiology heart failure had shorter LTL than those with non-ischaemic heart failure 
(Combined: N=3,426, B=-0.088; CI=-0.151 to -0.024; P=0.007). No difference in LTL was observed 
between patients with HFpEF compared with HFrEF (Combined: N=2,759, B=-0.074 [95% CI = -0.174 
to 0.025]; P=0.144). 
Telomere length and mortality 
As a continuous trait, after adjusting for age and sex, shorter LTL was associated with an increase in 
all-cause mortality (Table 2; Combined HR [per SD decrease in LTL] = 1.16 [1.08 – 1.24]; P=2.66x10-5). 
The associations remained significant after adjustment for the BIOSTAT-CHF mortality risk score 
(Table 2; Combined HR = 1.12 [1.05 – 1.20]; P=1.04x10-3). Figure 1 shows the age-, sex- and risk 
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score-adjusted hazard ratio for all-cause mortality across the range of telomere lengths in both 
cohorts, relative to the mean telomere length. Sensitivity analysis using individual components of 
the BIOSTAT-CHF mortality risk score as independent variables gave a similar association (Combined: 
N = 3,075; HR = 1.11 [1.03 – 1.20]; P=5.70x10-3). 
In cause-specific analyses, the association between shorter LTL and mortality was observed amongst 
patients who died from cardiovascular (CV) causes (CV deaths = 677; HR = 1.09 [95% CI = 1.00 – 
1.19]; P=0.047) and non-CV causes (Non-CV deaths = 380; HR = 1.18 [1.05 – 1.32]; P=4.80x10-3; 
Supplementary Table 4). 
Interestingly, the association between shorter LTL and mortality appeared stronger amongst 
patients with non-ischaemic heart failure aetiology than those with ischaemic aetiology 
(Supplementary Table 5). In age- and sex-adjusted analyses, shorter LTL was associated with 
mortality in both groups. However, after adjustment for the BIOSTAT-CHF risk score, shorter LTL was 
associated with increased mortality only amongst non-ischaemic aetiology patients (HR = 1.16 [95% 
CI = 1.01 – 1.32]; P=0.030), with only a non-significant trend observed for ischaemic aetiology 
patients (HR = 1.07 [95% CI = 0.98 – 1.16]; P=0.120). However, when included in the survival analyses 
of all patients, there was no evidence of an interaction between aetiology and LTL in either the Index 
(P=0.701) or Tayside (P=0.108) cohorts. 
When LTL was analysed as quartiles, similar results were obtained (Supplementary Table 6). After 
adjusting for age and sex, those with the shortest LTL were more likely to reach the mortality 
endpoint than those with the longest LTL (Q4 vs. Q1; Combined HR = 1.38; 95% CI = 1.15 – 1.66; 
P=0.001; Figure 2). After adjusting for the BIOSTAT-CHF mortality risk score, those with the shortest 
LTL were 27% more likely to die during follow-up than those with the longest LTL (Q4 vs. Q1: 
Combined HR = 1.27 [1.06 – 1.53]; P=0.011). 
To provide a clinical context for the impact of shorter LTL on mortality in heart failure, we compared 
its effect with that of chronological age. A one-year increase in age was associated with an all-cause 
mortality HR of 1.037 (95% CI = 1.030 – 1.044). Therefore, a one SD shorter LTL had an effect 
equivalent to that of being 4.04 years older. 
Association of telomere length with heart failure hospitalisation 
In contrast to mortality, we found no association between LTL and heart failure hospitalisation after 
adjustment for age and sex (Combined HR = 1.01 [0.94 – 1.09]; P=0.706) and adjustment for age, sex 
and the BIOSTAT-CHF hospitalisation risk score (Combined HR = 0.99 [0.92 – 1.07]; P=0.855; Table 2). 
When analysed as quartiles, comparable results were obtained (Supplementary Table 7). Sensitivity 
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analysis using individual components of the BIOSTAT-CHF hospitalisation risk score gave a similar 
finding (Combined HR = 1.03 [0.95 – 1.11]; P=.507), as did a competing risks analysis, performed to 
ensure the competing risk of death did not influence hospitalisation (Supplementary Table 8). 
 
Page | 11  
 
Discussion 
In the largest study of telomere length and outcome amongst heart failure patients to date, we show 
that mean circulating leucocyte telomere length is independently associated with all-cause mortality 
in this population. Using two large, observational studies totalling more than 3,600 patients with a 
broad spectrum of heart failure aetiologies and phenotypes and over 1,000 deaths, we found that 
after adjustment for age and sex, a one standard deviation decrease in LTL was associated with a 
16% increase in all-cause mortality, equivalent to an effect of being four years older. This association 
remained significant, with a 12% increase in mortality, even after accounting for known prognostic 
factors. In contrast, we found no association between LTL and heart failure hospitalisation. 
Two previous studies have examined the association between LTL and outcomes in heart failure. In a 
sub-study of the CORONA trial, Haver et al. found that LTL was univariately associated with their 
primary endpoint (a composite of cardiovascular death, non-fatal myocardial infarction, and non-
fatal stroke) with weak trends of association demonstrated for all-cause and cardiovascular 
mortality. However, these associations were not statistically significant after correction for age and 
gender.[7] In keeping with our results, Haver et al. also found no association between LTL and 
hospitalisation for worsening heart failure.[7] In an analysis of 890 chronic heart failure patients in a 
sub-study of COACH, van der Harst et al.[8] found that shorter LTL was associated with a combined 
end-point of all-cause mortality or heart failure hospitalisation, even after adjustment for age, sex 
and additional univariate predictors of outcome. However, secondary analyses demonstrated that 
this association was driven primarily by heart failure hospitalisation and not mortality.[8] 
There are several possible explanations for the differences observed between these studies and our 
findings. For example, CORONA only included patients with heart failure and coronary artery disease 
(CAD). However, the most important factor is likely to be the increased power afforded to our study 
by its size and high event-rate – we included over 1,000 deaths and almost 950 heart failure 
hospitalisations. This compares to just 93 deaths and 214 hospitalisations in COACH. In CORONA, the 
primary endpoint was reached in 575 patients and 758 patients were hospitalised due to heart 
failure. 
Several observations have linked telomere dynamics to cardiomyocyte biology and cardiac function. 
Sharifi-Sanjani et al. demonstrated that cardiomyocyte telomeres from patients with heart failure 
were shorter than from healthy donor hearts, independent of age.[14] This appeared to be a distinct 
signature in cardiomyocytes, as telomere length in smooth muscle cells was not different between 
failing and non-failing hearts.[14] With aging, telomerase knockout mice hearts showed shortening 
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of telomeres, attenuated proliferation and increased apoptosis of cardiomyocytes, and greater 
cardiac remodelling and left ventricular failure.[15] On the other hand, enhanced expression of 
telomerase reverse transcriptase in rat cardiomyocytes preserved telomere length, and induced 
cardiomyocyte proliferation, hypertrophy and survival.[16] We have previously shown an association 
between longer LTL and greater left ventricular mass, suggesting that longer telomeres may protect 
against myocardial loss with age.[17]  
Despite these observations, interestingly, we found that shorter LTL was associated with both 
cardiovascular and non-cardiovascular mortality, with the association with the latter, if anything, 
being somewhat stronger (Supplementary Table 4). This finding, along with the lack of any 
association of shorter LTL with heart failure hospitalisation, suggests that the association with 
mortality that we have seen may not be directly due to an impact of shorter telomeres on cardiac 
function. However, it is worth noting that the hospitalisation endpoint may be prone to bias due to 
factors that could prevent hospitalisation, including access to services, patient preference and death.  
Nevertheless, in this context, it is important to note that a wide range of other age-related diseases, 
including some cancers[18] and Alzheimer’s disease[19] with potential impact on mortality have also 
been associated with shorter telomeres. Indeed, perhaps the strongest evidence exists for an 
association between shorter LTL and CAD.[20-25] Furthermore, studies have also shown evidence of 
an association with all-cause mortality in patients with CAD.[26] However, we found no evidence 
that the association between shorter LTL and all-cause mortality in heart failure was being driven by 
the association with CAD. In fact, the association of shorter LTL with increased mortality in heart 
failure was nominally stronger in patients without CAD (Supplementary Table 5).  
Supporting our findings, in an analysis of 3,259 participants and 1,525 deaths from the 
Cardiovascular Health Study, Framingham Heart Study, and Women’s Health Initiative, shorter LTL 
was associated with increased all-cause mortality, with the strongest association seen for deaths not 
attributed to cancer or cardiovascular causes.[27] Furthermore, a recent meta-analysis of 25 studies 
including 121,749 participants from the general population found that a one standard deviation 
shorter telomere length was associated with a 9% increase in all-cause mortality risk.[28] Taken 
altogether it would seem that at least a substantial proportion of the observed association of shorter 
telomeres with increased mortality in patients with heart failure is not due to the presence of heart 
failure per se.  
Our study does have some limitations. Firstly, we measured telomere length in circulating 
leukocytes. Whilst this is an established measurement that is frequently employed in 
epidemiological studies, it may not reflect telomere length in cardiac-specific cells. Additionally, 
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whilst we have demonstrated a robust and replicated independent association between shorter LTL 
and all-cause mortality in patients with heart failure, we are unable to provide evidence of a 
mechanism or causal relationship. Similarly, as our analyses were cross-sectional in nature, we are 
unable to quantify the rate of telomere attrition in each patient, which has been suggested to be 
increased in heart failure,[29] and predictive of all-cause mortality in CAD patients.[30] 
Consequently, future work should seek to determine whether telomere length has a causal role in 
both the development and prognosis of heart failure. Such approaches should not only include 
mechanistic in-vitro and in-vivo animal studies, but also genetic techniques such as Mendelian 
randomisation, when populations with sufficient patients and event numbers are available. 
Conclusion 
In a large cohort of patients with heart failure, we have demonstrated a significant independent 
association between shorter LTL and increased all-cause mortality, but not heart failure 
hospitalisation. However, determining whether there is a causal relationship between telomere 
length and prognosis in patients with heart failure, whether telomere shortening represents a 
disease-specific biomarker, or whether our observation simply reflects biological ageing as a marker 
of reduced physiological reserve and increased susceptibility to clinical deterioration, requires 
further investigation. 
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Figure Legends 
Figure 1: Age-, sex- and risk score-adjusted hazard ratio for all-cause mortality across the range of 
LTLs in the Index and Tayside cohorts, relative to the mean LTL. Lines represents median of all 
simulations; dark shading represents central 50% and light shading represents minimum and 
maximum simulated values. 
Figure 2: Kaplan-Meier curves for all-cause mortality, split by age- and sex-adjusted quartiles for LTL 
in both the Index and Tayside cohorts. Tables represent the number of patients at risk at each time 
point in each quartile.  
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Tables 




(N = 2,260) 
 
Tayside Cohort 
(N = 1,413) 
Demographics    
   Sex (male) 73.1 (1653)  66.0 (933) 
   Age (years) 69.00 (12.07)  74.26 (10.37) 
   BMI (kg/m2) 27.94 (5.58)  29.10 (6.36) 
   Current smoker 13.7 (309)  12.4 (174) 
Clinical profile    
   NYHA Class 
      I 
      II 
      III 











   Heart failure classification 
      HFrEF (LVEF < 40%) 
      HFmrEF (LVEF 40 to 49%) 









Heart failure history    
   Ischaemic aetiology 61.2 (1232)  66.7 (943) 
   HF hospitalisation in previous year 31.0 (700)  27.0 (375) 
Medical history    
   Hypertension 62.9 (1422)  59.4 (837) 
   Diabetes mellitus 33.1 (748)  33.5 (472) 
Medication at baseline    
   ACEi or ARB 71.2 (1609)  69.5 (977) 
   Beta-blocker 82.7 (1868)  72.5 (1019) 
   MRA 52.6 (1188)  30.7 (431) 
Laboratory measurements    
   eGFR (mL/min/1.73m2; CKD-EPI) 60.27 (22.84)  60.42 (22.58) 
   NT-proBNP (ng/L) 2724 [1215, 5760]  1341 [511, 3488] 
 
Continuous variables are expressed as mean (SD) or median [interquartile range]. Categorical variables are expressed as % 
(N). ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BMI = body mass index; CKD-EPI 
= Chronic Kidney Disease Epidemiology Collaboration equation; eGFR = estimated glomerular filtration rate; HF = heart 
failure; HFmrEF = HF with moderately reduced ejection fraction; HFpEF = HF with preserved ejection fraction; HFrEF = HF 
with reduced ejection fraction; MRA = Mineralocorticoid Receptor Antagonist; NT-proBNP = N-terminal prohormone of B-




Page | 19  
 
Table 2: Association of LTL with all-cause mortality and heart failure hospitalisation, assessed by Cox proportional hazard regression 
   Index Cohort (N = 2,260)  Tayside Cohort (N = 1,413)  Combined (N = 3,673) 
Endpoint Model  HR 95% CI P  HR 95% CI P  HR 95% CI P 
All-cause mortality 1  1.17 1.07 – 1.29 1.03 x 10-3  1.14 1.04 – 1.26 8.08 x 10-3  1.16 1.08 – 1.24 2.66 x 10-5 
 2  1.14 1.04 – 1.25 7.55 x 10-3  1.10 1.00 – 1.22 .050  1.12 1.05 – 1.20 1.04 x 10-3 
Heart failure hospitalisation 1  0.98 0.89 – 1.08 .682  1.06 0.95 – 1.18 .308  1.01 0.94 – 1.09 .706 
 2  0.95 0.87 – 1.05 .331  1.05 0.94 – 1.16 .418  0.99 0.92 – 1.07 .855 
 
Model 1 = age- and sex-adjusted analyses; Model 2 = age- and sex-adjusted analyses, stratified by the appropriate BIOSTAT-CHF risk score. Hazard ratios represent change in risk per one 
standard deviation decrease in telomere length. Hazard ratios for other variables included in the models are not shown. 
Deaths – Index = 596; Tayside = 461; Combined = 1,057 
Heart failure hospitalisation – Index = 571; Tayside = 373; Combined = 944 
 
 






Figure 1: Age-, sex- and risk score-adjusted hazard ratio for all-cause mortality across the range of LTLs in the Index and Tayside cohorts, relative to the 









Figure 2: Kaplan-Meier curves for all-cause mortality, split by age- and sex-adjusted quartiles for LTL in both the Index and Tayside cohorts. Tables represent 
the number of patients at risk at each time point in each quartile.  
